市場調査レポート

商品コード

1139895

ヒトパピローマウイルスワクチン市場：タイプ別、疾患適応症別、業界別：世界の機会分析および産業予測、2021-2030年

Human Papillomavirus Vaccine Market By Type, By Disease Indication, By Industry Vertical : Global Opportunity Analysis and Industry Forecast, 2021-2030

出版日: 2022年06月01日 | 発行: Allied Market Research

| ページ情報: 英文 250 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,456 543,075円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,769 906,540円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 10,995 1,727,754円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ヒトパピローマウイルスワクチンの世界市場規模は、2021年に38億9270万米ドルとなり、2030年には108億2300万米ドルに達し、2022年から2030年までのCAGRは12.4％で成長すると予測されます。

ヒトパピローマウイルス疾患の流行が拡大するにつれて、ヒトパピローマウイルスワクチンの市場も拡大しています。新しいHPVワクチンの開発や、早期検診やワクチン接種に対する政府機関や商業団体の取り組みの増加が、ヒトパピローマウイルス（HPV）ワクチン市場の前進につながっています。肛門、口腔咽頭、生殖器領域におけるHPV関連悪性腫瘍の発生率の上昇と、感染症の減少に役立つHPVワクチン接種の需要の増加は、今後数年間、市場の安定した成長を維持すると予想されます。

一方、医療費は、予防に向けた動きが活発化し、高騰しています。ワクチン接種費用は過去20年間に数回、1桁から3桁に上昇し、医師や患者にとって大きな問題であると同時に、公衆衛生の財源を圧迫しています。

市場の定義と範囲
主な調査結果
- 主な投資ポケット
ポーターのファイブフォース分析
主要企業のポジショニング
市場力学
- 促進要因
- 抑制要因
- 機会
COVID-19 影響分析
バリューチェーン分析
主要な規制の分析
特許情勢
規制ガイドライン
市場シェア分析

第4章ヒトパピローマウイルスワクチン市場：タイプ別

概要
- 市場規模および予測
4価ワクチン
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
非原子価
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
二価
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第5章ヒトパピローマウイルスワクチン市場：疾患適応症別

概要
- 市場規模・予測
子宮頸がん
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
肛門癌
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
外陰癌・膣癌
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
陰茎癌
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
中咽頭癌（Oropharyngeal Cancer
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第6章ヒトパピローマウイルスワクチン市場：業界別

概要
- 市場規模および予測
官民アライアンス
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別分析
政府機関
- 主要な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
医師
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章ヒトパピローマウイルスワクチン市場：地域別

概要
- 市場規模および予測
北米
- 主な動向と機会
- 北米市場規模・予測：タイプ別
- 北米市場規模・予測：疾患適応症別
- 北米市場規模・予測：業界別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主な動向と機会
- 欧州市場規模・予測：タイプ別
- 欧州市場規模・予測：疾患適応症別
- 欧州市場規模・予測：業界別
- 欧州市場規模・予測：国別
  - ドイツ
  - 英国
  - フランス
  - スペイン
  - イタリア
  - その他の欧州地域
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：タイプ別
- アジア太平洋地域の市場規模・予測：疾患適応症別
- アジア太平洋地域の市場規模・予測：業界別
- アジア太平洋地域の市場規模・予測：国別
  - 中国
  - 日本
  - インド
  - 韓国
  - オーストラリア
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：タイプ別
- LAMEAの市場規模・予測：疾患適応症別
- LAMEAの市場規模・予測：業界別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - アラブ首長国連邦
  - 南アフリカ共和国
  - LAMEAの残りの地域

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

Merck & Co., Inc
GlaxoSmithKline plc.
Sanofi
Johnson & Johnson
AstraZeneca
Serum Institute of India Pvt. Ltd
Bharat Biotech.
Xenetic Biosciences, Inc.
Inovio Pharmaceuticals, Inc
Novartis AG

図表

LIST OF TABLES

TABLE 1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 2. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR TETRAVALENT, BY REGION, 2021-2030 ($MILLION)
TABLE 3. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR TETRAVALENT, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 4. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR NONAVALENT, BY REGION, 2021-2030 ($MILLION)
TABLE 5. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR NONAVALENT, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 6. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR BIVALENT, BY REGION, 2021-2030 ($MILLION)
TABLE 7. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR BIVALENT, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 9. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR CERVICAL CANCER, BY REGION, 2021-2030 ($MILLION)
TABLE 10. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR CERVICAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 11. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR ANAL CANCER, BY REGION, 2021-2030 ($MILLION)
TABLE 12. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR ANAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 13. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR VULVAR & VAGINAL CANCER, BY REGION, 2021-2030 ($MILLION)
TABLE 14. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR VULVAR & VAGINAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 15. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR PENILE CANCER, BY REGION, 2021-2030 ($MILLION)
TABLE 16. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR PENILE CANCER, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 17. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR OROPHARYNGEAL CANCER, BY REGION, 2021-2030 ($MILLION)
TABLE 18. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR OROPHARYNGEAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 19. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR OTHERS, BY REGION, 2021-2030 ($MILLION)
TABLE 20. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR OTHERS, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 22. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR PUBLIC AND PRIVATE ALLIANCES, BY REGION, 2021-2030 ($MILLION)
TABLE 23. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR PUBLIC AND PRIVATE ALLIANCES, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 24. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR GOVERNMENT ENTITIES, BY REGION, 2021-2030 ($MILLION)
TABLE 25. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR GOVERNMENT ENTITIES, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 26. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR PHYSICIANS, BY REGION, 2021-2030 ($MILLION)
TABLE 27. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR PHYSICIANS, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 28. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR OTHERS, BY REGION, 2021-2030 ($MILLION)
TABLE 29. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR OTHERS, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 30. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY REGION, 2021-2030 ($MILLION)
TABLE 31. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 32. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 33. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 34. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 35. U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 36. U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 37. U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 38. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 39. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 40. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 41. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 42. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 43. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 44. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 45. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 46. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 47. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 48. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 49. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 50. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 51. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 52. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 53. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 54. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 55. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 56. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 57. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 58. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 59. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 60. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 61. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 62. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 63. REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 64. REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 65. REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 66. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 67. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 68. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 69. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 70. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 71. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 72. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 73. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 74. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 75. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 76. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 77. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 78. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 79. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 80. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 81. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 82. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 83. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 84. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 88. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 89. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 90. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 91. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
TABLE 92. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 93. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 94. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 95. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 96. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 97. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 98. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 99. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 100. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 101. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 102. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 103. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 104. REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
TABLE 105. REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
TABLE 106. REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
TABLE 107.MERCK & CO., INC: COMPANY SNAPSHOT
TABLE 108.MERCK & CO., INC: OPERATING SEGMENTS
TABLE 109.MERCK & CO., INC: PRODUCT PORTFOLIO
TABLE 110.MERCK & CO., INC: NET SALES,
TABLE 111.MERCK & CO., INC: KEY STRATERGIES
TABLE 112.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 113.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 114.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 115.GLAXOSMITHKLINE PLC.: NET SALES,
TABLE 116.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
TABLE 117.SANOFI: COMPANY SNAPSHOT
TABLE 118.SANOFI: OPERATING SEGMENTS
TABLE 119.SANOFI: PRODUCT PORTFOLIO
TABLE 120.SANOFI: NET SALES,
TABLE 121.SANOFI: KEY STRATERGIES
TABLE 122.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 123.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 124.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 125.JOHNSON & JOHNSON: NET SALES,
TABLE 126.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 127.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 128.ASTRAZENECA: OPERATING SEGMENTS
TABLE 129.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 130.ASTRAZENECA: NET SALES,
TABLE 131.ASTRAZENECA: KEY STRATERGIES
TABLE 132.SERUM INSTITUTE OF INDIA PVT. LTD: COMPANY SNAPSHOT
TABLE 133.SERUM INSTITUTE OF INDIA PVT. LTD: OPERATING SEGMENTS
TABLE 134.SERUM INSTITUTE OF INDIA PVT. LTD: PRODUCT PORTFOLIO
TABLE 135.SERUM INSTITUTE OF INDIA PVT. LTD: NET SALES,
TABLE 136.SERUM INSTITUTE OF INDIA PVT. LTD: KEY STRATERGIES
TABLE 137.BHARAT BIOTECH.: COMPANY SNAPSHOT
TABLE 138.BHARAT BIOTECH.: OPERATING SEGMENTS
TABLE 139.BHARAT BIOTECH.: PRODUCT PORTFOLIO
TABLE 140.BHARAT BIOTECH.: NET SALES,
TABLE 141.BHARAT BIOTECH.: KEY STRATERGIES
TABLE 142.XENETIC BIOSCIENCES, INC.: COMPANY SNAPSHOT
TABLE 143.XENETIC BIOSCIENCES, INC.: OPERATING SEGMENTS
TABLE 144.XENETIC BIOSCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 145.XENETIC BIOSCIENCES, INC.: NET SALES,
TABLE 146.XENETIC BIOSCIENCES, INC.: KEY STRATERGIES
TABLE 147.INOVIO PHARMACEUTICALS, INC: COMPANY SNAPSHOT
TABLE 148.INOVIO PHARMACEUTICALS, INC: OPERATING SEGMENTS
TABLE 149.INOVIO PHARMACEUTICALS, INC: PRODUCT PORTFOLIO
TABLE 150.INOVIO PHARMACEUTICALS, INC: NET SALES,
TABLE 151.INOVIO PHARMACEUTICALS, INC: KEY STRATERGIES
TABLE 152.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 153.NOVARTIS AG: OPERATING SEGMENTS
TABLE 154.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 155.NOVARTIS AG: NET SALES,
TABLE 156.NOVARTIS AG: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION
FIGURE 2.HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030
FIGURE 3.HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.HUMAN PAPILLOMAVIRUS VACCINE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.VALUE CHAIN ANALYSIS
FIGURE 13.KEY REGULATION ANALYSIS
FIGURE 14.PATENT ANALYSIS BY COMPANY
FIGURE 15.PATENT ANALYSIS BY COUNTRY
FIGURE 16.REGULATORY GUIDELINES
FIGURE 17.MARKET SHARE ANALYSIS
FIGURE 18.HUMAN PAPILLOMAVIRUS VACCINE MARKET,BY TYPE,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TETRAVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF NONAVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF BIVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 22.HUMAN PAPILLOMAVIRUS VACCINE MARKET,BY DISEASE INDICATION,2021(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ANAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF VULVAR & VAGINAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF PENILE CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OROPHARYNGEAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF OTHERS HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 29.HUMAN PAPILLOMAVIRUS VACCINE MARKET,BY INDUSTRY VERTICAL,2021(%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF PUBLIC AND PRIVATE ALLIANCES HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 31.COMPARATIVE SHARE ANALYSIS OF GOVERNMENT ENTITIES HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 32.COMPARATIVE SHARE ANALYSIS OF PHYSICIANS HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 33.COMPARATIVE SHARE ANALYSIS OF OTHERS HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
FIGURE 34.HUMAN PAPILLOMAVIRUS VACCINE MARKET BY REGION,2021
FIGURE 35.U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 36.CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 37.MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 38.GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 39.UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 40.FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 41.SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 42.ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 43.REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 44.CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 45.JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 46.INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 47.SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 48.AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 49.REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 50.BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 51.SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 52.UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 53.SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 54.REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
FIGURE 55. TOP WINNING STRATEGIES, BY YEAR
FIGURE 56. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 57. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 58.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 59.COMPETITIVE DASHBOARD
FIGURE 60.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 61.MERCK & CO., INC.: NET SALES ,($MILLION)
FIGURE 62.GLAXOSMITHKLINE PLC..: NET SALES ,($MILLION)
FIGURE 63.SANOFI.: NET SALES ,($MILLION)
FIGURE 64.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
FIGURE 65.ASTRAZENECA.: NET SALES ,($MILLION)
FIGURE 66.SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES ,($MILLION)
FIGURE 67.BHARAT BIOTECH..: NET SALES ,($MILLION)
FIGURE 68.XENETIC BIOSCIENCES, INC..: NET SALES ,($MILLION)
FIGURE 69.INOVIO PHARMACEUTICALS, INC.: NET SALES ,($MILLION)
FIGURE 70.NOVARTIS AG.: NET SALES ,($MILLION)

Product Code: A14328

The global human papillomavirus vaccine market size was valued at $3,892.7 million in 2021 and is projected to reach $10,823.0 million by 2030, growing at a CAGR of 12.4% from 2022 to 2030.

As the prevalence of human papillomavirus diseases grows, so does the market for human papillomavirus vaccines. The development of new HPV vaccines, as well as increased initiatives by government and commercial organizations for early screening and vaccination, are propelling the human papillomavirus (HPV) vaccine market forward. The rising incidence of HPV-related malignancies in the anal, oropharynx, and genital regions, as well as increased demand for HPV vaccinations to help decrease infections, are expected to keep the market growing steadily in the coming years.

Healthcare expenditures, on the other hand, are skyrocketing, with the drive toward prevention. Vaccination costs have risen from the single digits to triple digits several times over the last two decades, posing considerable issues for doctors and their patients while also putting a strain on public health funding.

The global human papillomavirus vaccine market trends is segmented on the basis of type, disease indication, industry vertical and region. Based on type, the market has been divided into tetravalent, nonavalent, and bivalent. Based on disease indication, the market has been divided into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. Based on industry vertical, the market has been divided into public and private alliances, government entities, physicians, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in this report include: GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Sanofi S.A., Novartis AG, Serum Institute of India Pvt. Ltd., Bharat Biotech, Inovio Pharmaceuticals, Inc and Xenetic Biosciences, Inc. among others.

Key Market Segments

By Type

Tetravalent
Nonavalent
Bivalent

By Disease Indication

Cervical Cancer
Anal Cancer
Vulvar Vaginal Cancer
Penile Cancer
Oropharyngeal Cancer
Others

By Industry Vertical

Public and Private Alliances
Government Entities
Physicians
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of LAMEA
Key Market Players
- Merck & Co., Inc
- GlaxoSmithKline plc.
- Sanofi
- Johnson & Johnson
- AstraZeneca
- Serum Institute of India Pvt. Ltd
- Bharat Biotech.
- Xenetic Biosciences, Inc.
- Inovio Pharmaceuticals, Inc
- Novartis AG

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Value Chain Analysis
3.8.Key Regulation Analysis
3.9.Patent Landscape
3.10.Regulatory Guidelines
3.11.Market Share Analysis

CHAPTER 4: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Tetravalent
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Nonavalent
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Bivalent
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country

CHAPTER 5: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Cervical Cancer
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Anal Cancer
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Vulvar & Vaginal Cancer
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
5.5 Penile Cancer
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
5.6 Oropharyngeal Cancer
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
5.7 Others
- 5.7.1 Key market trends, growth factors and opportunities
- 5.7.2 Market size and forecast, by region
- 5.7.3 Market analysis by country

CHAPTER 6: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Public and Private Alliances
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Government Entities
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Physicians
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
6.5 Others
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country

CHAPTER 7: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Disease Indication
- 7.2.4 North America Market size and forecast, by Industry Vertical
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Type
  - 7.2.5.1.2 Market size and forecast, by Disease Indication
  - 7.2.5.1.3 Market size and forecast, by Industry Vertical
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Type
  - 7.2.5.2.2 Market size and forecast, by Disease Indication
  - 7.2.5.2.3 Market size and forecast, by Industry Vertical
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Type
  - 7.2.5.3.2 Market size and forecast, by Disease Indication
  - 7.2.5.3.3 Market size and forecast, by Industry Vertical
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Disease Indication
- 7.3.4 Europe Market size and forecast, by Industry Vertical
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Type
  - 7.3.5.1.2 Market size and forecast, by Disease Indication
  - 7.3.5.1.3 Market size and forecast, by Industry Vertical
  - 7.3.5.2 United Kingdom
  - 7.3.5.2.1 Market size and forecast, by Type
  - 7.3.5.2.2 Market size and forecast, by Disease Indication
  - 7.3.5.2.3 Market size and forecast, by Industry Vertical
  - 7.3.5.3 France
  - 7.3.5.3.1 Market size and forecast, by Type
  - 7.3.5.3.2 Market size and forecast, by Disease Indication
  - 7.3.5.3.3 Market size and forecast, by Industry Vertical
  - 7.3.5.4 Spain
  - 7.3.5.4.1 Market size and forecast, by Type
  - 7.3.5.4.2 Market size and forecast, by Disease Indication
  - 7.3.5.4.3 Market size and forecast, by Industry Vertical
  - 7.3.5.5 Italy
  - 7.3.5.5.1 Market size and forecast, by Type
  - 7.3.5.5.2 Market size and forecast, by Disease Indication
  - 7.3.5.5.3 Market size and forecast, by Industry Vertical
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Type
  - 7.3.5.6.2 Market size and forecast, by Disease Indication
  - 7.3.5.6.3 Market size and forecast, by Industry Vertical
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Disease Indication
- 7.4.4 Asia-Pacific Market size and forecast, by Industry Vertical
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 China
  - 7.4.5.1.1 Market size and forecast, by Type
  - 7.4.5.1.2 Market size and forecast, by Disease Indication
  - 7.4.5.1.3 Market size and forecast, by Industry Vertical
  - 7.4.5.2 Japan
  - 7.4.5.2.1 Market size and forecast, by Type
  - 7.4.5.2.2 Market size and forecast, by Disease Indication
  - 7.4.5.2.3 Market size and forecast, by Industry Vertical
  - 7.4.5.3 India
  - 7.4.5.3.1 Market size and forecast, by Type
  - 7.4.5.3.2 Market size and forecast, by Disease Indication
  - 7.4.5.3.3 Market size and forecast, by Industry Vertical
  - 7.4.5.4 South Korea
  - 7.4.5.4.1 Market size and forecast, by Type
  - 7.4.5.4.2 Market size and forecast, by Disease Indication
  - 7.4.5.4.3 Market size and forecast, by Industry Vertical
  - 7.4.5.5 Australia
  - 7.4.5.5.1 Market size and forecast, by Type
  - 7.4.5.5.2 Market size and forecast, by Disease Indication
  - 7.4.5.5.3 Market size and forecast, by Industry Vertical
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Type
  - 7.4.5.6.2 Market size and forecast, by Disease Indication
  - 7.4.5.6.3 Market size and forecast, by Industry Vertical
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Disease Indication
- 7.5.4 LAMEA Market size and forecast, by Industry Vertical
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Type
  - 7.5.5.1.2 Market size and forecast, by Disease Indication
  - 7.5.5.1.3 Market size and forecast, by Industry Vertical
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Type
  - 7.5.5.2.2 Market size and forecast, by Disease Indication
  - 7.5.5.2.3 Market size and forecast, by Industry Vertical
  - 7.5.5.3 United Arab Emirates
  - 7.5.5.3.1 Market size and forecast, by Type
  - 7.5.5.3.2 Market size and forecast, by Disease Indication
  - 7.5.5.3.3 Market size and forecast, by Industry Vertical
  - 7.5.5.4 South Africa
  - 7.5.5.4.1 Market size and forecast, by Type
  - 7.5.5.4.2 Market size and forecast, by Disease Indication
  - 7.5.5.4.3 Market size and forecast, by Industry Vertical
  - 7.5.5.5 Rest of LAMEA
  - 7.5.5.5.1 Market size and forecast, by Type
  - 7.5.5.5.2 Market size and forecast, by Disease Indication
  - 7.5.5.5.3 Market size and forecast, by Industry Vertical

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Merck & Co., Inc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 GlaxoSmithKline plc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Sanofi
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Johnson & Johnson
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 AstraZeneca
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Serum Institute of India Pvt. Ltd
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Bharat Biotech.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Xenetic Biosciences, Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Inovio Pharmaceuticals, Inc
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Novartis AG
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments

ヒトパピローマウイルスワクチン市場：タイプ別、疾患適応症別、業界別：世界の機会分析および産業予測、2021-2030年

Human Papillomavirus Vaccine Market By Type, By Disease Indication, By Industry Vertical : Global Opportunity Analysis and Industry Forecast, 2021-2030

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章ヒトパピローマウイルスワクチン市場：タイプ別

第5章ヒトパピローマウイルスワクチン市場：疾患適応症別

第6章ヒトパピローマウイルスワクチン市場：業界別

第7章ヒトパピローマウイルスワクチン市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE

CHAPTER 5: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION

CHAPTER 6: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL

CHAPTER 7: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

ヒトパピローマウイルスワクチン市場：タイプ別、疾患適応症別、業界別：世界の機会分析および産業予測、2021-2030年

Human Papillomavirus Vaccine Market By Type, By Disease Indication, By Industry Vertical : Global Opportunity Analysis and Industry Forecast, 2021-2030

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 ヒトパピローマウイルスワクチン市場：タイプ別

第5章 ヒトパピローマウイルスワクチン市場： 疾患適応症別

第6章 ヒトパピローマウイルスワクチン市場：業界別

第7章 ヒトパピローマウイルスワクチン市場：地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE

CHAPTER 5: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION

CHAPTER 6: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL

CHAPTER 7: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章ヒトパピローマウイルスワクチン市場：タイプ別

第5章ヒトパピローマウイルスワクチン市場：疾患適応症別

第6章ヒトパピローマウイルスワクチン市場：業界別

第7章ヒトパピローマウイルスワクチン市場：地域別

第8章企業情勢

第9章企業プロファイル